Lucid Diagnostics Inc.

Lucid Diagnostics Inc. is a medical diagnostics company dedicated to revolutionizing cancer prevention through innovative, non-invasive technologies. Its core mission is to empower clinicians to save lives by enabling the early detection and treatment of esophageal precancer, thereby preventing its progression to lethal cancer. The company's corporate headquarters are located in New York, NY, USA.

The company's key products include the EsoGuard® Esophageal DNA Test and the EsoCheck® Esophageal Cell Collection Device. These tools are designed for the early detection of esophageal precancer and cancer in a simple office-based procedure without the need for endoscopy. Lucid Diagnostics also provides central laboratory testing, support for office-based cell collection, mobile screening services, and insurance billing assistance. The company primarily targets patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at an elevated risk of developing esophageal precancer and cancer.

Lucid Diagnostics is a commercial-stage company led by Chairman and CEO Dr. Lishan Aklog. As a subsidiary of PAVmed Inc. (NASDAQ: PAVM), Lucid Diagnostics is actively expanding its market presence and advancing its diagnostic solutions. Recent notable developments include the closing of an $18 million underwritten offering of common stock in April 2026 and being awarded a U.S. Department of Veterans Affairs (VA) contract in January 2026 for its EsoGuard test, which expands access to over 9 million veterans. The company also reported positive data in December 2025 from the largest real-world experience of esophageal precancer detection, further solidifying its market positioning in early cancer detection.